Is Pseudohyperaldosteronism hereditary?

Pseudohyperaldosteronism, also known as apparent mineralocorticoid excess (AME), is a rare genetic disorder that affects the body's ability to regulate sodium and potassium levels. It is caused by mutations in the genes responsible for the production or function of the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2).

While pseudohyperaldosteronism is a genetic disorder, it does not follow a simple inheritance pattern. It is inherited in an autosomal recessive manner, which means that both parents must carry a copy of the mutated gene for their child to be affected. If both parents are carriers, there is a 25% chance with each pregnancy that the child will inherit two copies of the mutated gene and develop the disorder.

It is important to note that not all individuals who inherit the mutated gene will develop pseudohyperaldosteronism. Some individuals may be carriers of the gene without experiencing any symptoms or complications. The severity of the disorder can also vary among affected individuals, even within the same family.

Diagnosis of pseudohyperaldosteronism typically involves genetic testing to identify mutations in the 11β-HSD2 gene. Genetic counseling is recommended for individuals with a family history of the disorder or those who are carriers of the mutated gene.

Treatment for pseudohyperaldosteronism focuses on managing the symptoms and maintaining electrolyte balance. This may involve medications to regulate sodium and potassium levels, as well as dietary modifications. Regular monitoring and follow-up with healthcare professionals are essential to ensure optimal management of the condition.